The key product is Y-27632, a selective and potent ROCK inhibitor (ROCK: Rho-associated, coiled-coil containing protein kinase) acting on the ROCK signaling system. It was developed by Mitsubishi Tanabe Pharma and distributed by API corporation. In human ES cells, it helps to increase the survival rate and cloning efficiency after cryopreservation of human iPS cells. API had a non-exclusive license from CiRA, Kyoto University, on this product which now is transferred to Wako.

Wako news release, Oct. 30, 2014